U.S. Stocks Move: AstraZeneca rises over 1% pre-market after Q2 adjusted EPS beats expectations

Glonghui July 27｜AstraZeneca, the British pharmaceutical giant, rose 1.33% in pre-market trading to $171.51. In terms of news, AstraZeneca announced its second-quarter results, with revenue up 5% year-on-year to $15.38 billion, compared with the market expectation of $15.39 billion; adjusted earnings per share were $2.63, higher than the market expectation of $2.48; sales of the breast cancer drug Enhertu saw significant growth. Looking ahead to the full year, AstraZeneca reiterated its expectation for low double-digit year-on-year growth in core earnings per share by 2026 and mid-to-high single-digit growth in total revenue.